| Follow Us:

Buzz

Drug-rights sale could be worth up to $52 million for Ohio University, inventors


Ohio University and two researcher-inventors have sold partial royalty income rights to its license for the growth hormone antagonist drug Somavert to a private equity firm managed by DRI Capital, reports MicrOHscope.

The five-year agreement could net OU and its inventors up to $52 million for new biomedical research and technology commercialization initiatives.

Read the full story here.
Share this page
0
Email
Print